The Impact of Metabolic Syndrome on Immune Regulation (IL-17, IL-23, and FOXP3+), Psoriasis Severity, Flare Frequency, and Quality of Life in Psoriasis Patients: A Cross-Sectional Study.
{"title":"The Impact of Metabolic Syndrome on Immune Regulation (IL-17, IL-23, and FOXP3+), Psoriasis Severity, Flare Frequency, and Quality of Life in Psoriasis Patients: A Cross-Sectional Study.","authors":"Flora Ramona Sigit Prakoeswa, Faradiba Maharani, Saiful Hidayat, Winda Atika Sari, Triasari Oktavriana, Cita Rosita Sigit Prakoeswa, Menul Ayu Umborowati, Ratih Pramuningtyas, Rochmadina Suci Bestari, Riandini Aisyah, Erika Diana Risanti, Listiana Masyita Dewi, Ilham Hafizha Maulana Anam","doi":"10.1155/ijin/5855171","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Psoriasis is a chronic inflammatory skin disease that exhibits a strong association with metabolic syndrome (MetS). The involvement of various proinflammatory cytokines in MetS is thought to play a critical role in the pathogenesis of psoriasis. This study aims to evaluate the impact of MetS on immunological markers (IL-17, IL-23, and FOXP3+ regulatory T cells), disease severity, and quality of life (QoL) among patients with psoriasis. <b>Methods:</b> This cross-sectional study involved 42 psoriasis patients, divided into two groups: 29 without MetS (Pso) and 13 with MetS (Pso-MetS). Clinical parameters such as blood pressure, fasting blood glucose, and triglyceride levels were measured. Immunological markers (IL-17, IL-23, and FOXP3+) were analyzed using ELISA. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI), and QoL was evaluated with the Dermatology Life Quality Index (DLQI). <b>Results:</b> The Pso-MetS group was significantly older than the Pso group (<i>p</i> value = 0.003). Higher systolic (<i>p</i> value < 0.001), fasting glucose (<i>p</i> value = 0.002), and triglycerides (<i>p</i> value < 0.001) were observed in the Pso-MetS group. Lower HDL observed in the Pso-MetS group (<i>p</i> value = 0.004). FOXP3+ expression was significantly lower in the Pso-MetS group (<i>p</i>=0.02), while waist circumference, diastolic blood pressure, IL-17, IL-23, PASI, and DLQI scores levels showed no significant differences. <b>Conclusions:</b> MetS is associated with immune dysregulation, evidenced by reduced FOXP3+ expression in psoriasis patients. Further studies are needed to explore the immunological link between psoriasis and MetS.</p>","PeriodicalId":14004,"journal":{"name":"International Journal of Inflammation","volume":"2025 ","pages":"5855171"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204741/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Inflammation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijin/5855171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Psoriasis is a chronic inflammatory skin disease that exhibits a strong association with metabolic syndrome (MetS). The involvement of various proinflammatory cytokines in MetS is thought to play a critical role in the pathogenesis of psoriasis. This study aims to evaluate the impact of MetS on immunological markers (IL-17, IL-23, and FOXP3+ regulatory T cells), disease severity, and quality of life (QoL) among patients with psoriasis. Methods: This cross-sectional study involved 42 psoriasis patients, divided into two groups: 29 without MetS (Pso) and 13 with MetS (Pso-MetS). Clinical parameters such as blood pressure, fasting blood glucose, and triglyceride levels were measured. Immunological markers (IL-17, IL-23, and FOXP3+) were analyzed using ELISA. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI), and QoL was evaluated with the Dermatology Life Quality Index (DLQI). Results: The Pso-MetS group was significantly older than the Pso group (p value = 0.003). Higher systolic (p value < 0.001), fasting glucose (p value = 0.002), and triglycerides (p value < 0.001) were observed in the Pso-MetS group. Lower HDL observed in the Pso-MetS group (p value = 0.004). FOXP3+ expression was significantly lower in the Pso-MetS group (p=0.02), while waist circumference, diastolic blood pressure, IL-17, IL-23, PASI, and DLQI scores levels showed no significant differences. Conclusions: MetS is associated with immune dysregulation, evidenced by reduced FOXP3+ expression in psoriasis patients. Further studies are needed to explore the immunological link between psoriasis and MetS.